← FDA DRUG APPROVALS

FDA ANDA · ANDA074656

CISPLATIN

Sponsor: PHARMACHEMIE BV

APPLICATION
ANDA074656
TYPE
ANDA
ORIGINAL APPROVAL
2000-05-16
LATEST ACTION
2023-10-23
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CISPLATINPrescription
CISPLATIN 1MG/ML · INJECTABLE · INJECTION

Approval history

2023-10-23Labeling · Supplement 20 · standardAP
2015-09-22Labeling · Supplement 15 · standardAP
2012-03-15Labeling · Supplement 12AP
2012-01-23Labeling · Supplement 10AP
2008-10-17Labeling · Supplement 6AP
2002-07-17Manufacturing (CMC) · Supplement 1AP
2002-07-01Manufacturing (CMC) · Supplement 2AP
2000-05-16OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →